1 August 2022 | ARTICLE
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis OBJECTIVE: To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy. METHODS: This systematic review included randomised controlled trials that compared PCSK9 inhibitors with p...